Cerebellar dysfunction and schizophrenia-like behavior in Ebp1-deficient mice

Inwoo Hwang
Sungkyunkwan University
January 1, 2022
Mol Psychiatry
https://pubmed.ncbi.nlm.nih.gov/35165395

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/35165395

Research summary

This study investigates the role of EBP1 in cerebellar development and its association with schizophrenia-like behaviors. Using Ebp1 conditional Knockout (CKO) mice with CNS-specific deletion, researchers observed reduced cerebellar volume, Purkinje cell loss, and abnormal dendritic development. These structural deficits led to motor impairments and schizophrenia-like behaviors. Mechanistically, Ebp1 deficiency resulted in upregulation of Fbxw7, leading to degradation of PTF1A, a transcription factor critical for Purkinje cell development. Reintroduction of wild-type EBP1, but not the schizophrenia-associated E183Ter mutant, restored cerebellar architecture and behavioral phenotypes.

Key outcome of the study

Ebp1 deficiency in the CNS leads to cerebellar structural abnormalities and schizophrenia-like behaviors, highlighting its critical role in neurodevelopment and potential involvement in neuropsychiatric disorders.

Model

CNS-specific Ebp1 conditional Knockout (CKO) mice generated using Cre-loxP system to study the effects of Ebp1 deficiency on cerebellar development and behavior.

TARGET:
Pa2g4
Synonyms:
EBP1, ErbB3-binding protein 1

Keywords

Neurodevelopment, Schizophrenia, Cerebellar dysfunction, Purkinje cells, Epigenetic regulation

Technical specifications

Conditional Knockout, Cre-loxP system, CNS-specific gene deletion, Behavioral phenotyping

Related products

Catalogue product

No items found.

Customized product

No items found.

Catalogue product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe